PMID- 23913447
OWN - NLM
STAT- MEDLINE
DCOM- 20131125
LR  - 20180712
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
VI  - 154
IP  - 10
DP  - 2013 Oct
TI  - Estrogen, predominantly via estrogen receptor alpha, attenuates postpartum-induced 
      anxiety- and depression-like behaviors in female rats.
PG  - 3807-16
LID - 10.1210/en.2012-2136 [doi]
AB  - Contributions from estrogen receptor (ER) subtypes (ERalpha and ERbeta) to postpartum 
      anxiogenic and depressive responses remain unresolved in rats. Using the 
      elevated-plus maze (EPM) and forced swim (FS) tests, we confirmed that 
      primiparous rats exhibited anxiogenic and depressive responses 3 weeks 
      postpartum, improved 5 weeks postpartum (EPM), and recovered at 5 (FS) or 10 
      weeks postpartum (EPM) compared with diestrus nulliparous females. 
      Immunohistochemistry suggested that these behavioral changes were temporally 
      associated with decreased ERalpha but not ERbeta expression in the medial amygdala 
      (MEA). Additionally, ERalpha expression in the medial preoptic area (MPOA) 
      significantly increased 10 weeks postpartum. Brain-derived neurotrophic factor 
      (BDNF) expression was significantly elevated in the MEA 3 weeks postpartum. BDNF 
      receptor tropomyosin-related kinase expression was significantly elevated in the 
      MEA at 3 and 10 weeks but not at 5 weeks postpartum. The phosphorylation of ERK 
      (pERK)-2 in the MEA, MPOA, and hippocampal CA1 region was significantly elevated 
      3 and 5 weeks postpartum. The effects of single daily sc injections of the 
      ERalpha-selective agonist, propyl pyrazoletriol (PPT); ERbeta-selective agonist, 
      diarylpropionitrile; 17beta-estradiol (E(2)); and vehicle for 6 days in primiparous 
      rats were assessed. PPT and E(2) significantly produced anxiolytic and 
      antidepressant actions in the EPM and FS tests but PPT to a lesser degree than E(2) 
      in the EPM test. Diarylpropionitrile affected the EPM test but was not 
      significantly different from vehicle. BDNF expression was significantly increased 
      3 weeks postpartum by all treatments in the MPOA but not the CA1 and MEA. E(2) and 
      PPT treatment significantly increased tropomyosin-related kinase and pERK1/2 
      expression in the MEA and MPOA and increased pERK1/2 expression in the CA1. The 
      onset of anxiety- and depression-like behaviors in postpartum rats may be partly 
      caused by a complex estrogen-mediated mechanism; nevertheless, changes in the 
      ERalpha-related system, likely in the MEA, are predominantly involved.
FAU - Furuta, Miyako
AU  - Furuta M
AD  - PhD, Department of Physiology, St Marianna University School of Medicine, 2-16-1 
      Sugao, Miyamae, Kawasaki, Kanagawa 216-8511, Japan. mfuruta@marianna-u.ac.jp.
FAU - Numakawa, Tadahiro
AU  - Numakawa T
FAU - Chiba, Shuichi
AU  - Chiba S
FAU - Ninomiya, Midori
AU  - Ninomiya M
FAU - Kajiyama, Yu
AU  - Kajiyama Y
FAU - Adachi, Naoki
AU  - Adachi N
FAU - Akema, Tatsuo
AU  - Akema T
FAU - Kunugi, Hiroshi
AU  - Kunugi H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130802
PL  - United States
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Estrogens)
RN  - 0 (Phenols)
RN  - 0 (Pyrazoles)
RN  - 0T83Y6JZPF (4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol)
RN  - 4TI98Z838E (Estradiol)
RN  - EC 2.7.10.1 (Receptor, trkB)
SB  - IM
MH  - Amygdala/*drug effects/metabolism
MH  - Animals
MH  - Anti-Anxiety Agents/therapeutic use
MH  - Antidepressive Agents/therapeutic use
MH  - Anxiety/*drug therapy/etiology
MH  - Behavior, Animal/drug effects
MH  - Brain-Derived Neurotrophic Factor/metabolism
MH  - CA1 Region, Hippocampal/drug effects/metabolism
MH  - Depression, Postpartum/*drug therapy
MH  - Estradiol/therapeutic use
MH  - Estrogen Receptor alpha/*agonists/metabolism
MH  - Estrogen Receptor beta/agonists/metabolism
MH  - Estrogens/metabolism/*therapeutic use
MH  - Female
MH  - MAP Kinase Signaling System/drug effects
MH  - Neurons/*drug effects/metabolism
MH  - Phenols
MH  - Preoptic Area/drug effects/metabolism
MH  - Pyrazoles/therapeutic use
MH  - Rats
MH  - Rats, Long-Evans
MH  - Receptor, trkB/metabolism
MH  - Up-Regulation/*drug effects
EDAT- 2013/08/06 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/08/06 06:00
PHST- 2013/08/06 06:00 [entrez]
PHST- 2013/08/06 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - en.2012-2136 [pii]
AID - 10.1210/en.2012-2136 [doi]
PST - ppublish
SO  - Endocrinology. 2013 Oct;154(10):3807-16. doi: 10.1210/en.2012-2136. Epub 2013 Aug 
      2.